Innovative Vaccine Technology Vaxinano leverages the Stellar-NP technology to develop highly stable, adjuvant-free vaccines that offer long-lasting protection against complex pathogens such as parasites, viruses, bacteria, and fungi. This unique platform presents opportunities to collaborate or supply components for advanced vaccine formulations targeting challenging infectious diseases.

Recent Financing Strength Having secured over €6M in recent funding, Vaxinano is well-positioned for expansion and R&D initiatives, making it an attractive partner for investors and organizations seeking innovative vaccine solutions or co-development opportunities in the biotech space.

Strategic Partnerships The company's collaboration with StaniPharm for vaccine delivery system development shows openness to strategic partnerships, indicating potential for joint ventures with organizations focusing on advanced delivery technologies or complementary biotech solutions.

Focus on Tropical Diseases Vaxinano's research publication on immuno-therapeutic treatment for Canine Leishmaniasis highlights a specialization in neglected tropical diseases, opening avenues for partnerships with NGOs, governments, or pharma firms targeting global health challenges in underserved markets.

Growth and Market Expansion With a lean team and a focus on innovative vaccine platforms, Vaxinano presents opportunities for sales expansion into biotech, veterinary, and global health sectors, especially as demand for efficient, rapid-deploy vaccines continues to rise in response to emerging infectious threats.